Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. / Peters, Lars; Laut, Kamilla; Resnati, Chiara; Del Campo, Santos; Leen, Clifford; Falconer, Karolin; Trofimova, Tatyana; Paduta, Dzmitry; Gatell, Jose; Rauch, Andri; Lacombe, Karine; Domingo, Pere; Chkhartishvili, Nikoloz; Zangerle, Robert; Matulionyte, Raimonda; Mitsura, Viktar; Benfield, Thomas; Zilmer, Kai; Khromova, Irina; Lundgren, Jens; Rockstroh, Jürgen; Mocroft, Amanda; Eurosida Study Group.
In: AIDS (London, England), Vol. 32, No. 14, 2018, p. 1995-2004.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals
AU - Peters, Lars
AU - Laut, Kamilla
AU - Resnati, Chiara
AU - Del Campo, Santos
AU - Leen, Clifford
AU - Falconer, Karolin
AU - Trofimova, Tatyana
AU - Paduta, Dzmitry
AU - Gatell, Jose
AU - Rauch, Andri
AU - Lacombe, Karine
AU - Domingo, Pere
AU - Chkhartishvili, Nikoloz
AU - Zangerle, Robert
AU - Matulionyte, Raimonda
AU - Mitsura, Viktar
AU - Benfield, Thomas
AU - Zilmer, Kai
AU - Khromova, Irina
AU - Lundgren, Jens
AU - Rockstroh, Jürgen
AU - Mocroft, Amanda
AU - Eurosida Study Group
PY - 2018
Y1 - 2018
N2 - BACKGROUND AND AIMS: To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.METHODS: All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression.RESULTS: Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA.CONCLUSION: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.
AB - BACKGROUND AND AIMS: To investigate the uptake of hepatitis C virus (HCV) therapy among HIV/HCV-coinfected patients in the pan-European EuroSIDA study between 2011 and 2016.METHODS: All HCV-RNA+ patients were included. Baseline was defined as latest of anti-HCV+, January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression.RESULTS: Among 4308 HCV-RNA+ patients (1255, 970, 663, 633, 787 from South, West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113 (25.8%) started any HCV therapy. Among patients with at least F3 fibrosis, more than 50% in all regions remained untreated. The incidence (per 1000 person-years of follow-up, 95% confidence interval) of starting DAA increased from 7.8 (5.9-9.8) in 2014 to 135.2 (122.0-148.5) in 2015 and 128.9 (113.5-144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals from Central East or East, genotype 3, antiretroviral therapy naïve and those with detectable HIV-RNA were less likely to start DAA. Older persons, those with HCV-RNA more than 500 000 IU/ml and those with more advanced liver fibrosis were more likely to start DAA.CONCLUSION: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.
U2 - 10.1097/QAD.0000000000001928
DO - 10.1097/QAD.0000000000001928
M3 - Journal article
C2 - 29912062
VL - 32
SP - 1995
EP - 2004
JO - AIDS
JF - AIDS
SN - 1350-2840
IS - 14
ER -
ID: 215455776